Improving cognition in heart failure patients
Reducing Cognitive Impairment by Management of Heart Failure as a Modifiable Risk Factor: the Cog-HF Trial
This study tests a new care program using digital technology to help people with heart failure and memory problems improve their thinking skills and lower their risk of dementia.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 168 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Baker Heart and Diabetes Institute Academic / other |
| Locations | 1 site (Hobart, Tasmania) |
| Trial ID | NCT06088212 on ClinicalTrials.gov |
What this trial studies
This study tests a new care model aimed at patients with heart failure who also have cognitive impairment. It focuses on managing heart failure as a modifiable risk factor to improve cognitive function and reduce the risk of dementia and cardiovascular events. The program will utilize innovative digital technology to facilitate widespread implementation and aims to transform healthcare delivery for this high-risk population. The study will assess the feasibility and effectiveness of this approach in a clinical setting.
Who should consider this trial
Good fit: Ideal candidates are hospitalized patients diagnosed with heart failure who exhibit at least mild cognitive impairment.
Not a fit: Patients who are unable to provide consent, require palliative care, or have rapidly recovering cognitive function may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve cognitive health and reduce dementia risk in patients with heart failure.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in managing cognitive impairment through cardiovascular health interventions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Hospitalised with HF as primary or secondary diagnosis. 2. At least mild cognitive impairment (CI) based on Montreal Cognitive Assessment (MoCA) on hospital discharge. Exclusion Criteria: 1. Unable to provide written consent; requiring palliative care; or participating in another RCT 2. Recovery of cognitive function shortly after hospital discharge: to ensure that we only include patients with "true" CI, any patients with a repeated MoCA\>25 at 2 weeks post-discharge will be excluded. 3. Terminal illness (eg. cancer) that may influence 12-month prognosis.
Where this trial is running
Hobart, Tasmania
- Menzies Institute for Medical Research — Hobart, Tasmania, Australia (Recruiting)
Study contacts
- Principal investigator: Thomas H Marwick, MBBS PhD MPH — Baker Heart and Diabetes Institute
- Study coordinator: Quan Huynh
- Email: quan.huynh@baker.edu.au
- Phone: 610385321833
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.